Fleury Q4 2025 slides: double-digit growth amid centennial milestone

Grupo Fleury reported Q4 gross revenue of R$2.238bn (+12.2% YoY) and FY2025 revenue of R$9.003bn (+8.2%), with Q4 EBITDA R$455.9m (+12.5%) at a 22.1% margin and Q4 net income R$96.3m (+14.7%). Operating cash flow was R$2.1bn in FY2025 with 99.9% EBITDA conversion and net debt/EBITDA of 1.0x; management set EPS guidance of $0.24 for 2026 and $0.27 for 2027. The company beat EPS ($0.138 vs $0.1339) and revenue ($2.06bn vs $2.01bn) but shares fell ~3.4% after hours, even as dividend yield (10.65%) and strong cash generation support a positive long-term outlook.

Analysis

Fleury’s strategic posture—moving from a single-brand lab to a multi-branded, multi-specialty platform—creates optionality that is underappreciated by short-term market moves. The most important second-order effect is balance-sheet optionality: the ability to fund targeted tuck-ins and build ambulatory surgical centers without tapping volatile capital markets both compresses competition and raises integration risk for smaller regional labs that rely on B2B flows. Expect a two-speed market reaction where near-term flows favor profit-taking but medium-term fundamentals re-rate if management executes repeatable, accretive M&A and cross-sell across its digital/telemedicine stack.

Regulatory and macro vectors are the largest latent risks. Changes to public reimbursement, a politically-driven shift in private-pay penetration, or a sudden FX-driven rise in imported medical equipment costs could materially compress margins within 3–12 months. Conversely, discrete catalysts that would change consensus quickly include a sizable bolt-on acquisition, an explicit capital-allocation shift (bigger buyback or special dividend), or a material acceleration in high-margin ambulatory procedures — any of which would drive re-rating over a 6–18 month window.

From a valuation and positioning standpoint, the smartest way to express conviction is to isolate company-specific execution versus sector-wide sentiment. The market is currently sensitive to cash-flow durability and growth sustainability; that creates opportunities to harvest yield while using event-driven option structures or pairs to capture asymmetric upside if consolidation and digital cross-sell succeed. Maintain tight risk controls because a sector-wide rerating or adverse regulatory action would compress multiples across players regardless of idiosyncratic execution.

Key Decisions for Investors

• Long FLRY3 equity on a post-earnings pullback of ~5–15% with a 12-month horizon; target asymmetric total return of +30–40% (price appreciation plus distributions) if management executes M&A and cross-sell milestones; set a tactical stop-loss at ~20% below entry to limit downside exposure.
• Pair trade: Long FLRY3 / Short DASA3 (1:1) for 6–12 months to isolate Fleury’s superior roll-up and capital allocation optionality versus a large national peer; expected spread capture 20–30% if Fleury’s ROIC improvement persists; risk is a sector-wide multiple compression that would hurt both legs.
• Buy a 9–15 month FLRY3 call spread (buy ~20% OTM, sell ~40% OTM) sized at no more than 3–5% of portfolio NAV to express high-conviction upside while capping premium paid; this yields ~3x+ upside if M&A or ambulatory growth triggers re-rating, with defined max loss limited to the premium.
• Income/defensive alternative: Buy FLRY3 and sell near-term covered calls to monetize dividend yield while keeping upside participation; suitable if you expect limited upside in next 3 months but like the longer-term story—accept cap on near-term upside in exchange for downside cushion from option premium.